I am reversing my rating on Akero Therapeutics stock from Buy to Sell due to valuation concerns and a long-ish wait for ...

Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high ...

Akero Therapeutics, Inc. (NASDAQ: AKRO) President and CEO Andrew Cheng recently sold shares in the company, yielding a total of $178,728. The transaction, which took place on June 11, involved the ...

Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening ...

Insider Trading Published 01/31/2025, 09:23 AM 0 Akero Therapeutics chief development officer sells shares worth $3.01 million AKRO 0.79% ...

William Richard White, Chief Financial Officer of Akero Therapeutics, Inc. (NASDAQ: AKRO), sold 1,634 shares of common stock on June 18, 2025, according to a Form 4 filing with the Securities and ...

Akero Therapeutics (NASDAQ: AKRO) Chief Technology Officer Scott A. Gangloff sold 848 shares of common stock on June 18, 2025, at prices ranging from $54.73 to $54.84, for a total value of $46,504.

Akero Therapeutics, Inc. is set to hold an investor webcast on January 27, 2025, at 8:00 a.m. ET to present preliminary topline results from its SYMMETRY study, which evaluates the efficacy of ...

Akero Therapeutics Inc. advanced stock charts by Barron's. View 1AKRO historical stock data and compare to other stocks, and exchanges.

Akero Therapeutics, Inc. announced that its management will present at the BofA Securities 2025 Health Care Conference on May 13, 2025, at 1:40 p.m. P.T., with a live webcast available on their ...

Akero Therapeutics, Inc. (NASDAQ:AKRO) is up 71.75% year-to-date. Overall AKRO ranks 4th on our list of the biotech stocks that are skyrocketing so far in 2025.